menu

Collaborative Consult: Cases, Patient Reflection, and Discussions – What’s New in Pediatric Atopic Dermatitis

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Collaborative Consult: Cases, Patient Reflection, and Discussions – What’s New in Pediatric Atopic Dermatitis

0.75 credits
45 minutes
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.75 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Related
Comments
  • Overview

    Over 9.8% of children in the US have atopic dermatitis (AD), which is associated with significant disability and poor quality of life. While progress has occurred in the development of advanced therapies capable of improving response in poorly controlled AD, challenges still exist, including lack of prescriber confidence due to unfamiliarity of mechanisms of action of new and emerging agents.

    This activity, with expert faculty Dr. Anthony Mancini, will explore AD pathophysiology, review newly approved therapies and their place in treatment, and will present the latest on emerging agents, along with a patient ambassador sharing their experience with AD.

  • Disclosure of Conflicts of Interest

    Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

    The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

    Anthony J. Mancini, MD, FAAP, FAAD
    Advisory Boards: Cassiopea, Castle Creek, Novartis
    Consultant/Advisor: ParaPRO, Verrica
    Speakers’ Bureaus: Cassiopea, Sanofi Genzyme

    The patient and patient advocate have no real or apparent conflicts of interest to disclose.

    The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

  • Target Audience

    This educational activity has been designed to meet the needs of dermatologists and other members of the healthcare team who manage treatment of patients with atopic dermatitis.

  • Learning Objectives

    Upon completion of this educational activity, participants should be able to:

    • Describe the immunopathogenesis of AD 
    • Summarize current clinical trial data on the safety and efficacy of new and emerging therapies for pediatric AD  
    • Apply evidence-based guideline recommendations to the treatment of pediatric AD 
  • Accreditation and Credit Designation Statements

    ReachMD Healthcare Image

    Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclaimer

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare Image

    Provided by Integrity Continuing Education, Inc.

  • Commercial Support

    This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Related
Comments
  • Overview

    Over 9.8% of children in the US have atopic dermatitis (AD), which is associated with significant disability and poor quality of life. While progress has occurred in the development of advanced therapies capable of improving response in poorly controlled AD, challenges still exist, including lack of prescriber confidence due to unfamiliarity of mechanisms of action of new and emerging agents.

    This activity, with expert faculty Dr. Anthony Mancini, will explore AD pathophysiology, review newly approved therapies and their place in treatment, and will present the latest on emerging agents, along with a patient ambassador sharing their experience with AD.

  • Disclosure of Conflicts of Interest

    Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

    The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

    Anthony J. Mancini, MD, FAAP, FAAD
    Advisory Boards: Cassiopea, Castle Creek, Novartis
    Consultant/Advisor: ParaPRO, Verrica
    Speakers’ Bureaus: Cassiopea, Sanofi Genzyme

    The patient and patient advocate have no real or apparent conflicts of interest to disclose.

    The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

  • Target Audience

    This educational activity has been designed to meet the needs of dermatologists and other members of the healthcare team who manage treatment of patients with atopic dermatitis.

  • Learning Objectives

    Upon completion of this educational activity, participants should be able to:

    • Describe the immunopathogenesis of AD 
    • Summarize current clinical trial data on the safety and efficacy of new and emerging therapies for pediatric AD  
    • Apply evidence-based guideline recommendations to the treatment of pediatric AD 
  • Accreditation and Credit Designation Statements

    ReachMD Healthcare Image

    Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclaimer

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare Image

    Provided by Integrity Continuing Education, Inc.

  • Commercial Support

    This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule25 Sep 2022
Webpack App